secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001437749-22-029279
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Diffusion settles proxy contest with LifeSci; may appoint director if no deal by July 2023
--------------------------------------------------------------------------------

- LifeSci Special Opportunities withdraws its director nominees and will vote for Diffusion's slate at Dec 30 annual meeting.
- If no strategic transaction (e.g., sale, merger) completed by July 1, 2023, Diffusion must appoint a LifeSci-designated director.
- LifeSci, owning ~4.8% of DFFN shares, agrees to standstill and voting commitments through at least Dec 31, 2024.
- Diffusion to reimburse LifeSci up to $50,000 for expenses related to nomination and negotiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774922029279/0001437749-22-029279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774922029279/dffn20221215_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-029279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer